A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
No Data Available.
Synonyms :
acetazolamide 
Class :
Anticonvulsants and Carbonic Anhydrase Inhibitors
Brand Name :
No Data Available.
Synonyms :
acetazolamide 
Class :
Anticonvulsants and Carbonic Anhydrase Inhibitors
acetazolamide: it may increase the risk of methemoglobinemia agents
acetazolamide: it may increase the risk of methemoglobinemia agents
acetazolamide: it may increase the risk of methemoglobinemia agents
acetazolamide: it may increase the risk of methemoglobinemia agents
acetazolamide: it may increase the risk of methemoglobinemia agents
may enhance the therapeutic efficacy of each other when used in combination
may enhance the therapeutic efficacy of each other when used in combination
may enhance the therapeutic efficacy of each other when used in combination
may enhance the therapeutic efficacy of each other when used in combination
may enhance the therapeutic efficacy of each other when used in combination
may diminish the therapeutic efficacy of each other when used in combination
may diminish the therapeutic efficacy of each other when used in combination
may diminish the therapeutic efficacy of each other when used in combination
may diminish the therapeutic efficacy of each other when used in combination
may diminish the therapeutic efficacy of each other when used in combination
choline magnesium trisalicylate
Salicylates may enhance the risk of adverse effects of Carbonic Anhydrase Inhibitors
may enhance risk or severity of adverse effects when combined
may diminish the excretion rate of amantadine
may have an increased CNS depression when combined with acetazolamide
may have an increased effect of CNS depression when combined with Acetazolamide
choline magnesium trisalicylate
may have an increasingly adverse effect when combined with carbonic anhydrase inhibitors
severe dehydration may occur when acetazolamide is taken with bisoxatin
It may enhance the effects when combined with methenamine by the pharmacodynamic synergism
it decreases the rate of elimination of pidotimod
may enhance the rate of excretion resulting in the lower serum level
may enhance the rate of excretion resulting in the lower serum level
may enhance the rate of excretion resulting in the lower serum level
may enhance the rate of excretion resulting in the lower serum level
may enhance the rate of excretion resulting in the lower serum level
carbonic Anhydrase Inhibitors may reduce the rate of excretion of amphetamines
carbonic Anhydrase Inhibitors may reduce the rate of excretion of amphetamines
carbonic Anhydrase Inhibitors may reduce the rate of excretion of amphetamines
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may decrease the rate of excretion of amphetamines
may decrease the rate of excretion of amphetamines
may decrease the rate of excretion of amphetamines
may decrease the rate of excretion of amphetamines
may decrease the rate of excretion of amphetamines
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
it may diminish the metabolism when combined with aripiprazole lauroxil
may enhance the serum concentration when combined with alpha-/beta-agonists
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
acetazolamide: they may increase the toxic effect of sodium bicarbonate
It may enhance the effects when combined with tasimelteon by affecting CYP3A4 metabolism
Reduced cefotiam excretion may occur when acetazolamide is administered concurrently
it may diminish the excretion rate when combined with gadofosveset, resulting in an enhanced serum level
The potential for enhanced CNS depression exists when halazepam is utilized concurrently with acetazolamide
levobupivacaine and acetazolamide could enhance the risk or seriousness of methemoglobinemia
The potential for increased CNS depression risk or seriousness occurs when acetazolamide is used together with pinazepam
When acetazolamide is used together with medazepam, the risk or seriousness of CNS depression is enhanced
The potential for CNS depression may enhanced when acetazolamide is used together with fencamfamin
acetazolamide may intensify paraldehyde's CNS depressant effects
When acetazolamide is used together with niaprazine, the risk or seriousness of CNS depression is enhanced
When acetazolamide is used together with levosulpiride, the risk or seriousness of CNS depression is enhanced
When alprazolam and acetazolamide is used together, this leads to reduction in the alprazolam’s metabolism
When chlordiazepoxide is used together with acetazolamide, this leads to enhanced risk or seriousness of CNS depression
When acetazolamide is used together with capsaicin, this leads to enhanced risk or seriousness of methemoglobinemia
When acetazolamide is used together with norelgestromin, this leads to a rise in norelgestromin’s metabolism
When acetazolamide is used together with melitracen, this leads to enhanced risk or seriousness of CNS depression
When acepromazine is used together with acetazolamide, this leads to enhanced risk or seriousness of CNS depression
When emylcamate is used together with acetazolamide, this leads to enhanced risk or seriousness of CNS depression
When acetazolamide is used together with etizolam, this leads to enhanced risk or seriousness of CNS depression
When isoflurane is used together with acetazolamide, this leads to enhanced risk or seriousness of CNS depression
acetazolamide leads to a reduction in the rate of excretion of eucalyptus oil which leads to increased level of serum
When hexafluronium is used together with acetazolamide, this leads to enhanced risk or seriousness of CNS depression
When sertindole is used together with acetazolamide, this leads to enhanced risk or seriousness of CNS depression
acetazolamide may raise the excretion rate of ioxilan, potentially resulting in a lower serum level and a potential reduction in efficacy
acetazolamide may raise the excretion rate of phylloquinone, potentially resulting in lower serum levels and a potential reduction in efficacy
mycophenolic acid excretion rate may be increased by acetazolamide, potentially resulting in a lower serum level and reduced efficacy
acetazolamide may increase the excretion rate of n-acetyl tyrosine, potentially resulting in a lower serum level and potentially reducing efficacy
acetazolamide may raise the excretion rate of sulbactam, potentially resulting in a lower serum level and potentially reducing efficacy
acetazolamide: it may decrease the excretion rate of iothalamic acid
acetazolamide: it may increase the risk or severity of CNS depression
acetazolamide: it may increase the risk or severity of CNS depression
acetazolamide: it may increase the risk or severity of CNS depression
acetazolamide: it may increase the risk or severity of CNS depression
acetazolamide: it may increase the risk or severity of CNS depression
when cinchocaine is combined with acetazolamide, there is an increased risk or severity of methemoglobinemia associated with the latter
when acetazolamide is used in conjunction with taurocholic acid, the excretion of taurocholic acid can be reduced
acetazolamide: it may increase the risk of CNS depression with pipotiazine
the risk or extent of CNS depression can be raised when oxycodone is combined with acetazolamide
the combination of butalbital and acetazolamide may increase the risk or extent of CNS depression
the risk or extent of hypoglycemia may increase when acetazolamide is combined with insulin aspart
acetazolamide may increase the excretion rate of doxofylline, which could result in a lower serum level and potentially a reduction in efficacy
acetazolamide may heighten the excretion speed of hydroxyethyl starch, potentially resulting in a lower serum level and a potential decrease in efficacy
Therapeutic activity decreased of acetazolamide.
it may increase the level of serum concentration of memantine 
it may decrease the rate of excretion of amphetamines 
it may increase the level of serum concentration of memantine
carbonic Anhydrase Inhibitors may increase the levels of serum concentration of amantadine
carbonic Anhydrase Inhibitors may decrease the levels of serum concentration of lithium
carbonic Anhydrase Inhibitors may increase the risk of adverse effects of metformin
Carbonic Anhydrase Inhibitors may increase the levels of serum concentration of Alpha-/Beta-Agonists
antiseizure agents may diminish the diagnostic effect of metyrapone
it decreases the efficacy of antiseizure agents
carbonic anhydrase inhibitors may enhance the levels of serum concentration of alpha-/beta-agonists
they increase the toxicity of metformin
choline magnesium trisalicylate
may enhance the adverse effect of carbonic anhydrase inhibitors
may diminish the excretion of amphetamines
may decrease the tiopronin excretion rate
- may increase the toxic effect of antipsychotic agents
may enhance the serum concentration of amantadine
may increase the levels of serum concentration
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the toxic effect of Antipsychotic Agents
may increase the hypoglycemic effect of Antidiabetic Agents
it may enhance the severity of dehydration when combined with castor oil
may increase the metabolism of each other when it is combined
they increase the toxicity of saxagliptin/metformin
excretory rate of ancestim may be increased with acetazolamide, which results in lower levels in serum
When acetazolamide is used together with etizolam, this leads to enhanced risk or seriousness of CNS depression
the efficacy of aurothiglucose may be reduced due to an increase in the rate of excretion when taken with acetazolamide
the metabolism of dihydroergocristine can decrease when combined with acetazolamide
the risk of depression of the central nervous system can be enhanced when dihydrocodeine is taken with acetazolamide
the rate of excretion of inositol may be reduced
the risk of dehydration may be increased
the risk of CNS depression may be increased
the risk of CNS depression may be increased
may have a decrease in excretion when combined with acetazolamide
the risk of methemoglobinemia may be increased
the rate of excretion of topiroxostat may be increased
the risk of adverse effects may be increased
the risk of methemoglobinemia may be increased
the risk of cardiac arrhythmia may be increased
the risk of cardiac arrhythmia may be increased
the rate of excretion of alclofenac may be increased
the risk or extent of hypoglycemia can be raised when acetazolamide is combined with insulin pork
the risk of central nervous system depression may be increased
the risk of CNS depression may be increased
the risk of CNS depression may be increased
When acetazolamide is used together with lomitapide, this leads to enhanced concentration serum of lomitapide
the efficacy of phosphoric acid may be decreased due to an increase in rate of excretion
the severity of central nervous system depression can be increased when acetazolamide is taken with zotepine
the rate of excretion of bufylline can be increased with acetazolamide
the therapeutic efficacy of luseogliflozin may be elevated
acetazolamide can enhance the potency or impact of intranasal dihydroergotamine by modulating the metabolism of the hepatic/intestinal enzyme CYP3A4
acetazolamide can impact the hepatic/intestinal enzyme CYP3A4 metabolism, leading to an elevation in the level or potency of intranasal midazolam
by altering the gastrointestinal absorption, the concentration of acetazolamide may be reduced with cyanocobalamin
Adverse drug reactions:  Â
Frequency Not Defined Â
Muscle weakness Â
Hearing dysfunction or tinnitus Â
Sulfonamide type reactions Â
Diarrhea Â
Metallic taste Â
Nausea Â
Urticaria Â
Anorexia Â
Confusion Â
Convulsions Â
Drowsiness Â
Flaccid paralysis Â
Malaise Â
Paresthesias Â
Photosensitivity Â
Hematuria Â
Polyuria Â
Glycosuria Â
Vomiting Â
Hepatic disease Â
Aplastic anemia Â
Agranulocytosis Â
Leukopenia Â
Thrombocytopenia Â
Thrombocytopenic purpura Â
Melena Â
Acidosis Â
Electrolyte imbalance Â
 Â
Pregnancy warnings:    Â
Pregnancy category: cÂ
Breastfeeding warnings: Â
Pregnancy Categories:      Â
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first trimester or the later trimester.      Â
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women      Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women      Â
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits      Â
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.      Â
Category N: There is no data available for the drug under this category     Â
Â
Patient Information Leaflet Â
Generic Name: acetazolamideÂ
Pronounced: a-SEET-a-ZOLE-a-mideÂ
Why do we use acetazolamide?Â
Acetazolamide is a diuretic drug that belongs to the subclass carbonic anhydrase used to treat glaucoma, congestive heart failure, edema, seizures, and prevent altitude sickness.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
